At the Clinical Trials on Alzheimer’s Disease Congress this week, Biogen (MA, USA) has provided a detailed report on the latest aducanumab results, including why there was such a difference in the results between ENGAGE and EMERGE.
A recent set of studies reports how blood–brain barrier leakage may affect inflammation in the brain, potentially leading to acceleration of neurological aging in mice.
Artificial neurons have been developed in a first-of-its-kind achievement that closely resemble biological neurons, mimicking their responses to a range of stimulations.
Researchers have discovered a correlation between reaction time and white matter microstructure damage in patients with concussion, suggesting an alteration in signaling patterns as a result of mild traumatic brain injury.
The US FDA-approved anti-inflammatory drug cromolyn sodium has been demonstrated to delay disease progression in an ALS mouse model.
A preclinical study in mice has revealed that a specific miRNA could target and modulate the gut microbiome with precision, holding potential as a new treatment option for multiple sclerosis.
A new study has revealed that specific patterns in brain activity can indicate whether a young mouse will develop Alzheimer’s-like memory deficits in old age.
Using fluorescent tags, a team of researchers discovered a novel mechanism for synaptic plasticity that may have pharmacological applications in the treatment of epilepsy.
Preclinical data has demonstrated that an oral small molecule drug could inhibit the formation of neurotoxic tau oligomers in an animal model most relevant to Alzheimer’s disease.
A study of more than 1000 elderly patients has revealed that there are no links between statin medication and cognitive decline.